CSL Behring has presented positive Phase III data on Afstyla (antihemophilic factor (recombinant), single chain) in hemophilia A patients aged less than 12 years of age.
The company, which is a subsidiary of Australian blood plasma and vaccines specialist CSL Limited (ASX: CSL), presented the results at the World Federation of Hemophilia 2016 World Congress.
They showed that Afstyla, used prophylactically across different treatment intervals, including two to three times weekly, achieved low annualized spontaneous bleeding rates and low annualized bleeding rates in previously treated children and adolescents with hemophilia A.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze